Mostra i principali dati dell'item

dc.contributor.authorSánchez Montejo, Javier 
dc.contributor.authorTeodosio, Cristina 
dc.contributor.authorLópez Abán, Julio 
dc.contributor.authorManzano Román, Raúl 
dc.contributor.authorPozo Gangoso, Julio Javier del 
dc.contributor.authorSolinís, María Ángeles
dc.contributor.authorPozo-Rodríguez, Ana del
dc.contributor.authorStrilets, Tania
dc.contributor.authorGarcia Blanco, Mariano A.
dc.contributor.authorVicente Santiago, María Belén 
dc.contributor.authorMuro Álvarez, Antonio 
dc.coverage.spatialSalamanca, lat=40.96882 ; long= -5.66388es_ES
dc.coverage.temporalstart=2025-02-27 and end=2026-03-11es_ES
dc.date.accessioned2026-06-19T07:48:34Z
dc.date.available2026-06-19T07:48:34Z
dc.date.issued2026
dc.identifier.citationMartín Rodríguez, A., Teodosio, C., López-Abán, J., Manzano Román, R., Pozo Gangoso, J. J. del, Solinís, M. Á., Pozo-Rodríguez, A. del, Strilets, T., Garcia Blanco, M. A., Vicente Santiago, M. B., & Muro Álvarez, A. (2026). Raw data of Multiepitope mRNA vaccine against Fasciola hepatica confers T-cell-mediated protection in mice [Dataset]. Universidad de Salamanca. https://doi.org/10.71636/V8C2-1H02
dc.identifier.urihttp://hdl.handle.net/10366/171872
dc.descriptionSamples were acquired on a Cytek Aurora 5L spectral flow cytometer (Cytek Biosciences, Fremont, CA) equipped with five lasers (355 nm, 405 nm, 488 nm, 561 nm, 640 nm). Spectral unmixing was performed using SpectroFlo software (v3.3.0; Cytek). Flow cytometric data were analyzed using Infinicyt software version 2.1.0.a (BD Biosciences, San Jose, CA, USA). Raw data. Daily instrument quality control was performed using SpectroFlo QC beads (Cytek) before sample measurement. Single-stained reference controls and unstained controls were used for spectral unmixing validation.es_ES
dc.description.abstract[EN]This dataset contains raw spectral flow cytometry files (FCS format) generated in a mouse immunization and challenge study evaluating an mRNA–solid lipid nanoparticle (mRNA-SLN) vaccine candidate encoding three MHC class II T-cell epitopes from Fasciola hepatica fused to eGFP (eGFP-Fh3Tq). BALB/c mice (n = 33) were allocated into four experimental groups: Untreated (n = 9), Infection control (n = 6), eGFP (n = 9), and eGFP-Fh3Tq (n = 9). Groups eGFP and eGFP-Fh3Tq received a prime–boost immunization regimen (21 days apart) with the corresponding mRNA-SLN formulation. Peripheral blood was collected from three groups (Untreated, eGFP, and eGFP-Fh3Tq) at day 1 post-vaccination (innate panel) and day 42 post-vaccination (adaptive panel); the Infection control group was not differentiated from the Untreated group at these time points and was therefore not sampled separately. For blood panels, samples from two mice were pooled and barcoded with anti-CD45 conjugated to either PerCP or BUV496 before acquisition, yielding three FCS files per group (6 mice/group). At day 42, spleens from three mice per group (Untreated, eGFP, eGFP-Fh3Tq) were harvested for intracellular cytokine staining (ICS) after ex vivo restimulation with the synthetic peptides T14, T15, and T16, PMA/ionomycin (positive control), or left unstimulated (negative control). For ICS, individual splenocyte samples from different conditions were barcoded with anti-CD45 and combined in pairs within each acquisition tube. Where sufficient cells were available, stimulation conditions were performed in duplicate. Remaining mice were orally challenged with 7 F. hepatica metacercariae for survival and protection assessment. All samples were acquired on a Cytek Aurora 5L spectral flow cytometer equipped with five lasers (355, 405, 488, 561, 640 nm).es_ES
dc.description.sponsorshipMinisterio de Ciencia e Innovación Junta de Castilla y León, co-financed by the Fondo Social Europeo Plus Department of Education of the Basque Governmentes_ES
dc.description.tableofcontentsContiene: Group key: G1 = Untreated (PBS control), G2 = eGFP (eGFP mRNA-SLN), G3 = eGFP-Fh3Tq (eGFP-Fh3Tq mRNA-SLN). R = biological replicate (individual mouse). Blood files contain two barcoded mice per tube (e.g., R1_R2). ICS files contain two barcoded conditions per tube. Stimulation conditions (ICS): PHAIono = PMA/ionomycin positive control; CTRL = unstimulated negative control; Pep = T14+T15+T16 peptide pool. Suffixes _1 and _2 denote technical duplicates of the same condition. Folder D1 — Peripheral blood, day 1 post-vaccination (innate panel) 1. PROT_Blood_D1_G1-Untreated_R1_R2_Unmixed.fcs 2. PROT_Blood_D1_G1-Untreated_R3_R4_Unmixed.fcs 3. PROT_Blood_D1_G1-Untreated_R5_R6_Unmixed.fcs 4. PROT_Blood_D1_G2-eGFP_R1_R2_Unmixed.fcs 5. PROT_Blood_D1_G2-eGFP_R3_R4_Unmixed.fcs 6. PROT_Blood_D1_G2-eGFP_R5_R6_Unmixed.fcs 7. PROT_Blood_D1_G3-eGFP-Fh3Tq_R1_R2_Unmixed.fcs 8. PROT_Blood_D1_G3-eGFP-Fh3Tq_R3_R4_Unmixed.fcs 9. PROT_Blood_D1_G3-eGFP-Fh3Tq_R5_R6_Unmixed.fcs Folder D42 — Peripheral blood, day 42 post-vaccination (adaptive panel) 1. PROT_Blood_D42_G1-Untreated_R1_R2_Unmixed.fcs 2. PROT_Blood_D42_G1-Untreated_R3_R4_Unmixed.fcs 3. PROT_Blood_D42_G1-Untreated_R5_R6_Unmixed.fcs 4. PROT_Blood_D42_G2-eGFP_R1_R2_Unmixed.fcs 5. PROT_Blood_D42_G2-eGFP_R3_R4_Unmixed.fcs 6. PROT_Blood_D42_G2-eGFP_R5_R6_Unmixed.fcs 7. PROT_Blood_D42_G3-eGFP-Fh3Tq_R1_R2_Unmixed.fcs 8. PROT_Blood_D42_G3-eGFP-Fh3Tq_R3_R4_Unmixed.fcs 9. PROT_Blood_D42_G3-eGFP-Fh3Tq_R5_R6_Unmixed.fcs Folder ICS — Splenocytes, day 42 post-vaccination (intracellular cytokine staining panel) 1. PROT_Spleen_ICS_01_G1R1-PHAIono1_G1R1-CTRL1_Unmixed.fcs 2. PROT_Spleen_ICS_02_G1R1-Pep1_G1R1-Pep2_Unmixed.fcs 3. PROT_Spleen_ICS_03_G1R2-PHAIono1_G1R2-PHAIono2_Unmixed.fcs 4. PROT_Spleen_ICS_04_G1R2-CTRL1_G3R1-CTRL1_Unmixed.fcs 5. PROT_Spleen_ICS_05_G1R2-Pep1_G1R2-Pep2_Unmixed.fcs 6. PROT_Spleen_ICS_06_G1R3-PHAIono1_G1R3-PHAIono2_Unmixed.fcs 7. PROT_Spleen_ICS_07_G1R3-CTRL1_G1R3-CTRL2_Unmixed.fcs 8. PROT_Spleen_ICS_08_G1R3-Pep1_G1R3-Pep2_Unmixed.fcs 9. PROT_Spleen_ICS_09_G2R1-PHAIono1_G2R1-CTRL1_Unmixed.fcs 10. PROT_Spleen_ICS_10_G2R1-Pep1_G2R1-Pep2_Unmixed.fcs 11. PROT_Spleen_ICS_11_G2R2-PHAIono1_G2R2-PHAIono2_Unmixed.fcs 12. PROT_Spleen_ICS_12_G2R2-CTRL1_G2R2-CTRL2_Unmixed.fcs 13. PROT_Spleen_ICS_13_G2R2-Pep1_G2R2-Pep2_Unmixed.fcs 14. PROT_Spleen_ICS_14_G2R3-PHAIono1_G2R3-PHAIono2_Unmixed.fcs 15. PROT_Spleen_ICS_15_G2R3-CTRL1_G2R3-CTRL2_Unmixed.fcs 16. PROT_Spleen_ICS_16_G2R3-Pep1_G2R3-Pep2_Unmixed.fcs 17. PROT_Spleen_ICS_17_G3R1-PHAIono1_G3R1-PHAIono2_Unmixed.fcs 18. PROT_Spleen_ICS_18_G3R1-Pep1_G3R1-Pep2_Unmixed.fcs 19. PROT_Spleen_ICS_19_G3R2-PHAIono1_G3R2-Pep1_Unmixed.fcs 20. PROT_Spleen_ICS_20_G3R2-CTRL1_G3R3-CTRL1_Unmixed.fcs 21. PROT_Spleen_ICS_21_G3R3-PHAIono1_G3R3-PHAIono2_Unmixed.fcs 22. PROT_Spleen_ICS_22_G3R3-Pep1_G3R3-Pep2_Unmixed.fcses_ES
dc.language.isoenges_ES
dc.publisherUniversidad de Salamancaes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.subjectFasciola hepaticaes_ES
dc.subjectParasitees_ES
dc.subjectTrematodees_ES
dc.subjectmRNA vaccinees_ES
dc.subjectSolid lipid nanoparticleses_ES
dc.subjectT-cell epitopeses_ES
dc.subjectCytometryes_ES
dc.subjectMultiepitopees_ES
dc.subject.meshParasites *
dc.subject.meshFasciola hepatica *
dc.subject.meshTrematode Infections *
dc.titleRaw data of Multiepitope mRNA vaccine against Fasciola hepatica confers T-cell-mediated protection in mice [Dataset]es_ES
dc.typeinfo:eu-repo/semantics/datasetes_ES
dc.subject.unesco2401.12 Parasitología Animales_ES
dc.identifier.doi10.71636/v8c2-1h02
dc.relation.projectIDPID2022-136462NB-I00es_ES
dc.relation.projectIDIT1587-22es_ES
dc.relation.projectIDGIC21/34es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.type.hasVersioninfo:eu-repo/semantics/submittedVersiones_ES
dc.subject.decsparásitos *
dc.subject.decsinfecciones por trematodos *
dc.subject.decsFasciola hepatica *
dc.publication.year2026


Files in questo item

Thumbnail
Thumbnail

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item

Attribution-NonCommercial-NoDerivatives 4.0 International
Excepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NonCommercial-NoDerivatives 4.0 International